{"id":1618,"date":"2022-02-02T09:40:56","date_gmt":"2022-02-02T09:40:56","guid":{"rendered":"https:\/\/macrimasa.com\/?page_id=1618"},"modified":"2022-02-11T12:24:18","modified_gmt":"2022-02-11T12:24:18","slug":"main-lines-of-action-of-id","status":"publish","type":"page","link":"https:\/\/macrimasa.com\/?page_id=1618&lang=en","title":{"rendered":"Main lines of action of I+D"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MAIN LINES OF ACTION OF I+D<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

For Macrimasa Group, it is essential to create innovation in its developments (devices and applications), in the infrastructures that the company has, and in the different processes that involve them: design, manufacturing, logistics, marketing and distribution. For this reason the company will implement the UNE-EN 166002:2006 Standard, referring to I+D+i Management.<\/p>

\u00a0<\/p>

\u00a0<\/p>

Macrimasa Group has a team of highly qualified professionals in different areas, such as pharmacists, telecommunications engineers and industrial engineers, all of whom make up the R&D Department, a multidisciplinary team with great professional experience, fully aware of the market and with great ambition to carry out innovative developments.<\/p>

\u00a0<\/p>

Its activity is concentrated in various therapeutic areas: Anaesthesia, Cardiology, Major Outpatient Surgery, Palliative Care, Diagnosis, Teaching, Emergency, Gynaecology, Neurology, Clinical Nutrition, Oncology, Otorhinolaryngology, Paediatrics, Operating Theatre, ICU, Pain Units, Urology and Geriatrics. Macrimasa also manufactures healthcare technologies, with a firm commitment to innovation and technological development.<\/p>

\u00a0<\/p>

Macrimasa Group focuses its business strategy on the research and development of new products in different therapeutic areas that contribute to improving the health and well-being of patients. To achieve this, the company dedicates a very important component of its own resources to investments in I+D+i.<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n\t\t\t\t\t
<\/i><\/span><\/i><\/span>Macrimasa-Pharma Laboratories<\/span><\/i><\/div>

This division focuses on the research, development and marketing of Medical Healthcare Technology, which markets medical devices, diagnostic systems and reagents whose main objective is to improve people’s health in the hospital environment.<\/p><\/div>\n\t\t\t\t\t<\/div>

\n\t\t\t\t\t
<\/i><\/span><\/i><\/span>Macrimasa-Vet Laboratories<\/span><\/i><\/div>

At present, we are constantly working on the research and development of products for the veterinary sector. Our aim is to provide real solutions to the new needs of animal health. The constant communication with the veterinary clinician helps us to carry out this work.<\/p><\/div>\n\t\t\t\t\t<\/div>

\n\t\t\t\t\t
<\/i><\/span><\/i><\/span>Macrimasa HealthCare Laboratories<\/span><\/i><\/div>

Medical Technology Division that commercialises material for aesthetic medicine centres and hospitals, geriatric centres, assisted reproduction units, emergency, rescue and diagnosis, whose main objective is to guarantee the reliability of the values of our products.<\/p><\/div>\n\t\t\t\t\t<\/div>

\n\t\t\t\t\t
<\/i><\/span><\/i><\/span>Macrimasa-Academy<\/span><\/i><\/div>

MACRIMASA ACADEMY is the MACRIMASA GROUP’s digital innovation centre that contributes to the development of new digital capabilities to help demonstrate, transfer and share knowledge to our clients, based on its skill centres focused on digital technologies and their applicability to medical and business results.<\/p><\/div>\n\t\t\t\t\t<\/div>

\n\t\t\t\t\t
<\/i><\/span><\/i><\/span>Macrimasa Hub<\/span><\/i><\/div>

MACRIMASA HUB promotes an Open Innovation programme to accelerate innovation in the era of disruption It is the first corporate accelerator of human and animal health startups in Spain Through open and collaborative innovation, we explore the co-creation of solutions and new sustainable value propositions to the strategic challenges of the company and the challenges of the different business units of the company through the combination of internal knowledge and the capabilities provided by the best startups. The startups that participate in the I’MNOVATION programme co-develop pilot projects together with experts from the company for three months for their validation in real market environments, a period in which they have the collaboration, mentoring and financing of the MACRIMASA GROUP for their execution.<\/p><\/div>\n\t\t\t\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
Business<\/span> Areas<\/span><\/div>\t\t\t<\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
Main lines<\/span> of action<\/span><\/div>\t\t\t<\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n \n
\n
\n
\n
Collaborations with CIBER groups<\/h6>

The company is working with different Research Groups registered in national CIBER Centres, with which it deals with very specific topics, such as the latest research in biosensors or in vitro diagnostic studies.<\/p><\/p>\n <\/div>\n <\/div>\n <\/div>\n \n

\n
\n
\n
Collaborations with Universities<\/h6>

Macrimasa currently has a collaboration agreement with the University of Malaga, and is in contact with research groups from other universities, such as the University of Seville, the Polytechnic University of Madrid and the San Pablo CEU University.<\/p><\/p>\n <\/div>\n <\/div>\n <\/div>\n \n

\n
\n
\n
Collaboration with scientific organisations<\/h6>

patient associations, scientific societies and other organisations that contribute directly to the development of the world’s pharmaceutical medical market.<\/p><\/p>\n <\/div>\n <\/div>\n <\/div>\n \n

\n
\n
\n
Collaboration with hospitals and health centres<\/h6>

at private and public level, both nationally and internationally.<\/p><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n